- Phase 1/1b clinical trial with CGX-926 ongoing for MC4R-deficient genetic obesity -

- 针对MC4R缺陷型遗传性肥胖的CGX-926一期/1b期临床试验正在进行中 -

- Programs in Parkinson's Disease and Alpha-1 antitrypsin deficiency progressing toward the clinic -

- 帕金森病和α-1抗胰蛋白酶缺乏症的项目正朝着临床方向进展 -

MONTREAL

蒙特利尔

,

，

March 19, 2026

2026年3月19日

/PRNewswire/ -- Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson's disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing of a US $39.5 million financing..

/PRNewswire/ -- 致力于蛋白质错误折叠相关疾病（包括MC4R缺陷型（MC4R-d）遗传性肥胖、GBA1驱动的帕金森病以及α-1抗胰蛋白酶（A1AT）缺乏症）的临床阶段计算驱动生物技术公司Congruence Therapeutics今日宣布完成了3950万美元的融资。

The financing was co-led by new investor Dimension and existing investor OrbiMed. Additional investors included Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital's Thrive Venture Fund, Driehaus, and Silver Arc.

本轮融资由新投资者 Dimension 和现有投资者 OrbiMed 共同领投。其他投资者包括 Amplitude Ventures、FSTQ、Lumira、Investissement Quebec、BDC Capital 的 Thrive Venture Fund、Driehaus 和 Silver Arc。

'Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin,' said Dr. Clarissa Desjardins, co-founder and CEO of Congruence Therapeutics. 'In addition to CGX-926, we are advancing multiple proprietary and collaborative programs.

“我们的使命是将生物学、化学和蛋白质结构的见解转化为针对疾病分子起源的药物，”Congruence Therapeutics联合创始人兼首席执行官Clarissa Desjardins博士说。“除了CGX-926，我们还在推进多个自主和合作项目。”

We thank our new and existing investors for their continued support.'.

我们感谢新老投资者的持续支持。

Proceeds from the financing will support the Phase 1/1b study of CGX-926, the Company's lead program for MC4R-deficient genetic obesity, in healthy subjects and patients with MC4R-deficiency. Congruence also plans to complete IND-enabling activities for two additional development candidates targeting GBA1-driven Parkinson's Disease and Alpha-1 antitrypsin deficiency, with the goal of filing a CTA/IND for both programs in early 2027..

融资所得将用于支持公司针对MC4R缺陷型遗传性肥胖的主导项目CGX-926的1/1b期研究，受试者包括健康志愿者和MC4R缺陷患者。Congruence还计划完成另外两个开发候选项目的IND申报前活动，这两个项目分别针对GBA1驱动的帕金森病和α-1抗胰蛋白酶缺乏症，目标是在2027年初为这两个项目提交CTA/IND申请。

'Leveraging cutting edge molecular dynamics and machine learning, Congruence has built a best-in-class platform to unlock an exciting modality of medicines in small molecule correctors,' said Zavain Dar, Founder & Managing Partner, Dimension. 'In short order Clarissa and team have demonstrated technology and scientific leadership, joined with strong execution and capital efficiency.

“通过利用前沿的分子动力学和机器学习，Congruence打造了一个卓越的平台，以解锁小分子校正剂这一令人兴奋的药物模式，”Dimension创始人兼管理合伙人Zavain Dar表示，“Clarissa及其团队迅速展示了技术与科学领导力，并结合了强大的执行力和资本效率。”

This is the promise of technologically enabled biotech. We're thrilled to join as CGX-926 enters the clinic and we see the translation of the platform's unique capabilities.' .

这就是技术赋能生物技术的承诺。我们很高兴加入，因为CGX-926进入临床阶段，我们看到了该平台独特能力的转化。

Congruence also continues to advance its R&D collaborations, including a recently expanded multi-target partnership with Ono Pharmaceuticals in which Congruence is leading the effort to discover small molecules for targets spanning the therapeutic areas of oncology, neurology, and immunology. The Company is separately advancing another collaboration with an undisclosed global pharmaceutical company on a difficult to drug metabolic target..

一致性还在继续推进其研发合作，包括最近与小野制药公司扩大了多靶点合作。在此合作中，一致性正领导着发现跨肿瘤学、神经学和免疫学治疗领域靶点的小分子的工作。该公司还正在与一家未公开的全球制药公司就一个难以成药的代谢靶点推进另一项合作。

About Revenir™ Drug Discovery Platform

关于Revenir™药物发现平台

Revenir™, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes of proteins in different functional states, offering unique insights into protein function and their modulation. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced modulation of underlying physiologic protein states.

Revenir™，Congruence 专有的计算药物发现平台，捕捉蛋白质在不同功能状态下的动态生物物理变化，为蛋白质功能及其调控提供独特的见解。通过检查蛋白质构象集合的表面特征和一系列生物物理描述符，Revenir™ 预测小分子诱导的潜在生理蛋白质状态的调控。

This platform-driven strategy underpins Congruence's growing pipeline of first-in-class and best-in-class programs directed to genetically validated targets implicated in conditions associated with significant unmet medical need, supporting a readily scalable and repeatable value creation paradigm..

这一基于平台的战略支撑了Congruence不断增长的针对与重大未满足医疗需求相关疾病关联的基因验证靶点的首创和最佳项目管道，支持了一个易于扩展且可重复的价值创造模式。

About Congruence Therapeutics

关于同余治疗学

Congruence is a clinical-stage, computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Their proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency.

一致性生物技术公司是一家处于临床阶段、以计算驱动的生物技术公司，致力于构建一条独特的变革性小分子矫正剂管线，这些分子经过合理设计，旨在修复异常的蛋白质功能。其专有的可扩展平台Revenir™能够捕捉蛋白质在其构象集合中的生物物理特征，从而识别新的变构和隐秘口袋，并通过虚拟筛选生成新颖的化学物质。一致性公司利用其专有的发现引擎，启动了一条完全自主拥有的药物管线，针对高价值、基因验证过的难成药靶点，涵盖多种适应症，包括遗传性肥胖、GBA帕金森病和α1-抗胰蛋白酶缺乏症。

Congruence is further deploying its discovery platform to support its multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors and allosteric modulators for the treatment of diseases in oncology, metabolic disease, neurology and immunology..

Congruence正在进一步部署其发现平台，以支持与大型制药公司的多靶点研究合作，专注于发现用于治疗肿瘤学、代谢疾病、神经学和免疫学领域的小分子校正剂和变构调节剂。

Company Contact

公司联系人

Charles Grubsztajn

查尔斯·格鲁布什塔因

Chief Operating Officer

首席运营官

[email protected]

电子邮件地址

Media Contact

媒体联系人

Amy Conrad

艾米·康拉德

Juniper Point

杜松角

[email protected]

电子邮件地址

858-366-3243

858-366-3243

SOURCE Congruence Therapeutics

来源：Congruence Therapeutics

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示